Developer docs
API playgroundTry for free, no card

Search company profiles

DiNAQOR

Full company profile

uuid000a2if

Namestring
DiNAQOR
Legal namestring
DINAQOR AG
Websiteurl
dinaqor.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

DiNAQOR AG is a privately held Swiss life science company builder founded in 2019 and headquartered in Pfäffikon, Switzerland, with additional R&D operations in Schlieren (Bio-Technopark Zürich), German operations inherited from the EHT Technologies GmbH acquisition, and a US medical device subsidiary in Laguna Hills, California. The company develops gene therapy and precision delivery platforms targeting monogenic cardiomyopathies and renal genetic diseases, built on three proprietary technology pillars: Engineered Heart Tissue (EHT) technology based on human-induced pluripotent stem cell cardiomyocytes for preclinical disease modeling; a closed-loop Loco-Regional Perfusion (LRP) catheter-based delivery system that achieved up to 69,000-fold higher local payload concentration and 75-fold increase in target-organ transduction efficiency in preclinical models; and an AAV vector platform with organ-specific constructs. Its therapeutic pipeline includes DiNA-001 through DiNA-006 (covering HCM, ARVC, and DCM) and DINAK-001 through DINAK-004 (ADPKD and Glomerular Diseases), with DiNA-001 partnered to BioMarin.

The company operates a portfolio of four subsidiaries: DiNAMIQS (AAV viral vector CDMO, 95% owned by Siegfried since May 2023, with a cGMP facility inaugurated September 2025 at up to 500L scale), DiNABIOS (human cell and tissue CDMO), DiNATEQ AG (drug delivery MedTech for the LRP platform, spun out December 2025), and DAiNA (N=1 precision oncology). DiNAQOR generates revenue through licensing and milestone payments (BioMarin agreement covering DiNA-001 with upfront plus development, regulatory, and commercial milestones and tiered royalties), manufacturing services (DiNAMIQS/Siegfried, Lonza for DiNA-001 production), and platform technology licensing to pharmaceutical and biotech partners. The company targets pharmaceutical and biotechnology enterprises seeking gene therapy delivery, manufacturing, and partnership solutions for cardiac and renal genetic disease programs.

Short descriptiontext

DiNAQOR is a Swiss privately-held life science company builder developing gene therapies and a closed-loop loco-regional perfusion delivery platform for monogenic cardiac and renal diseases, serving pharmaceutical and biotech partners through a portfolio of specialized subsidiaries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPfäffikon, Switzerland
HQ citystring
Pfäffikon
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy platform, AAV vector manufacturing, precision drug delivery, engineered heart tissue, biopharmaceutical licensing
Industry5 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Gene Therapy & Biotechnology Platforms
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

DiNAQOR receives upfront payments, development, regulatory and commercial milestones, and tiered royalties on worldwide sales from licensing agreements with pharmaceutical partners such as BioMarin for programs like DiNA-001 for MYBPC3 hypertrophic cardiomyopathy.

dinaqor.com
2Manufacturing Services
TypeProfessional Services
Description

Through DiNAMIQS (now majority-owned by Siegfried), DiNAQOR accesses GMP manufacturing capabilities for viral vectors, providing end-to-end manufacturing from vector design to aseptic drug product filling.

dinaqor.com
3Technology Platform Licensing
TypeLicensing Royalties
Description

DiNAQOR licenses its LRP delivery platform technology to pharmaceutical and biotechnology partners for use with their therapeutic assets, offering differentiated delivery solutions that enhance therapeutic index.

dinaqor.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1DiNAMIQS
Description

CDMO for advanced medicine providing GMP-compatible capabilities and scalable viral vector manufacturing services.

dinaqor.com
+3 more records
Core offering1 text field

DiNAQOR is a Swiss-headquartered life science company builder that creates and scales focused biotechnology companies around differentiated gene therapy technology platforms. It combines proprietary Engineered Heart Tissue (EHT) technology, a closed-loop Loco-Regional Perfusion (LRP) delivery system, and AAV vector engineering to advance monogenic cardiomyopathy and renal disease programs. Revenue is generated through licensing deals, milestone payments, royalties, and CDMO services delivered via its portfolio subsidiaries (DiNAMIQS, DiNABIOS, DiNATEQ AG, DAiNA).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 69,000-fold higher local payload concentration compared to conventional intravenous administration
+3 more records
Product overview1 text field

DiNAQOR is a Swiss-headquartered life science company builder operating a multi-platform portfolio of distinct subsidiaries and technology offerings. The core comprises DiNATEQ AG (precision drug delivery MedTech advancing the closed-loop Loco-Regional Perfusion platform), DiNAMIQS (AAV viral vector CDMO spun out and now majority-owned by Siegfried), DiNABIOS (AI-driven human cell and tissue CDMO), and DAiNA (N=1 precision oncology). Underpinning the portfolio are two proprietary technology platforms: Engineered Heart Tissue (EHT) based on hiPSC cardiomyocytes, and the Loco-Regional Perfusion (LRP) system for organ-isolated delivery. The therapeutic pipeline includes multiple gene therapy programs spanning monogenic cardiomyopathies (DINA-001 through DINA-006 covering HCM, ARVC, DCM) and monogenic renal diseases (DINAK-001 through DINAK-004 for ADPKD and Glomerular Diseases), with programs partnered with BioMarin, Lonza, and UCL.

Product and service6 records
1DiNAMIQS (AAV Viral Vector CDMO)
CategoryCDMO Services
2DiNABIOS (Human Tissue & Stem Cell CDMO)
CategoryCDMO Services
3DiNATEQ AG (Loco-Regional Perfusion Delivery Platform)
CategoryDrug Delivery MedTech Platform
4DAiNA (N=1 Precision Oncology Platform)
CategoryPrecision Oncology Platform
5Engineered Heart Tissue (EHT) Technology Platform
CategoryPreclinical Testing Platform
6LRP Delivery Platform Licensing
CategoryDrug Delivery Technology Licensing
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-23
Description

Academic partnership for development of closed-loop loco-regional perfusion (LRP) platform. Professor Maximilian Y. Emmert led the landmark study published in JACC: Basic to Translational Science demonstrating the LRP technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-23
Description

Academic partner in landmark LRP delivery platform research published in JACC: Basic to Translational Science.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

DiNAMIQS, established in 2022 and spun out from DiNAQOR as independent entity in 2023, has been acquired with 95% equity by Siegfried. New cGMP viral vector manufacturing facility inaugurated, enabling end-to-end manufacturing from vector design to drug product filling.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-04
Description

DiNAQOR sold 95% stake in DiNAMIQS to Siegfried, who is building a high-end GMP compliant facility for viral vector manufacturing at 500L scale. DiNAQOR remains a minority equity holder and close partner. Investment was mid double-digit millions Swiss Francs.

5Children's Medical Research Institute (CMRI)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-10
Description

Research collaboration to develop novel bioengineered AAV capsids for cardiac-specific gene therapy delivery. CMRI provides AAV capsid library; DiNAQOR provides EHT technology for screening. DiNAQOR has option to exclusive license co-developed capsids for cardiovascular and kidney diseases.

dinaqor.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-19
Description

DiNAQOR acquired EHT Technologies GmbH, a Germany-based engineered heart tissue (EHT) technology platform company founded in 2015 based on research at University Medical Center Hamburg-Eppendorf.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-03
Description

Preclinical collaboration and license agreement to develop gene therapies for rare genetic cardiomyopathies. DiNAQOR received undisclosed upfront payment and is eligible for development, regulatory, and commercial milestones plus tiered royalties. Covers DiNA-001 for MYBPC3 HCM with option to extend to other programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-13
Description

Research collaboration and exclusive license agreement with UCL Business Ltd to develop gene therapies for monogenic cardiomyopathies. DiNAQOR obtains worldwide rights to therapies developed. Royalties to UCL upon commercialization. Based on research of Professor Thomas Voit at UCL GOSH Institute of Child Health.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-26
Description

Strategic collaboration for DiNAQOR's AAV gene therapy production system. Lonza provides preclinical, clinical and commercial production support for DiNA-001 at Houston, TX facility. Focus on MYBPC3 cardiomyopathies.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DiNAQOR

Gene Therapy & Biotechnology Platformsdinaqor.com

DiNAQOR is a Swiss privately-held life science company builder developing gene therapies and a closed-loop loco-regional perfusion delivery platform for monogenic cardiac and renal diseases, serving pharmaceutical and biotech partners through a portfolio of specialized subsidiaries.

What DiNAQOR does

DiNAQOR AG is a privately held Swiss life science company builder founded in 2019 and headquartered in Pfäffikon, Switzerland, with additional R&D operations in Schlieren (Bio-Technopark Zürich), German operations inherited from the EHT Technologies GmbH acquisition, and a US medical device subsidiary in Laguna Hills, California. The company develops gene therapy and precision delivery platforms targeting monogenic cardiomyopathies and renal genetic diseases, built on three proprietary technology pillars: Engineered Heart Tissue (EHT) technology based on human-induced pluripotent stem cell cardiomyocytes for preclinical disease modeling; a closed-loop Loco-Regional Perfusion (LRP) catheter-based delivery system that achieved up to 69,000-fold higher local payload concentration and 75-fold increase in target-organ transduction efficiency in preclinical models; and an AAV vector platform with organ-specific constructs. Its therapeutic pipeline includes DiNA-001 through DiNA-006 (covering HCM, ARVC, and DCM) and DINAK-001 through DINAK-004 (ADPKD and Glomerular Diseases), with DiNA-001 partnered to BioMarin.

The company operates a portfolio of four subsidiaries: DiNAMIQS (AAV viral vector CDMO, 95% owned by Siegfried since May 2023, with a cGMP facility inaugurated September 2025 at up to 500L scale), DiNABIOS (human cell and tissue CDMO), DiNATEQ AG (drug delivery MedTech for the LRP platform, spun out December 2025), and DAiNA (N=1 precision oncology). DiNAQOR generates revenue through licensing and milestone payments (BioMarin agreement covering DiNA-001 with upfront plus development, regulatory, and commercial milestones and tiered royalties), manufacturing services (DiNAMIQS/Siegfried, Lonza for DiNA-001 production), and platform technology licensing to pharmaceutical and biotech partners. The company targets pharmaceutical and biotechnology enterprises seeking gene therapy delivery, manufacturing, and partnership solutions for cardiac and renal genetic disease programs.

DiNAQOR firmographics

Firmographics
Name
DiNAQOR
Legal name
DINAQOR AG
Website
https://dinaqor.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
DiNAQOR is a Swiss privately-held life science company builder developing gene therapies and a closed-loop loco-regional perfusion delivery platform for monogenic cardiac and renal diseases, serving pharmaceutical and biotech partners through a portfolio of specialized subsidiaries.
Ownership category
akta.pro rank

DiNAQOR industry classification

Industry
Product category
Gene Therapy & Biotechnology Platforms
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy platform
  • AAV vector manufacturing
  • Precision drug delivery
  • Engineered heart tissue
  • Biopharmaceutical licensing

Where DiNAQOR is headquartered

Location

Headquarters

HQ city
Pfäffikon
HQ country
Switzerland
HQ region
Europe

Offices4 records

Markets served

DiNAQOR business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing and Milestone Payments: DiNAQOR receives upfront payments, development, regulatory and commercial milestones, and tiered royalties on worldwide sales from licensing agreements with pharmaceutical partners such as BioMarin for programs like DiNA-001 for MYBPC3 hypertrophic cardiomyopathy.
  2. Manufacturing Services: Through DiNAMIQS (now majority-owned by Siegfried), DiNAQOR accesses GMP manufacturing capabilities for viral vectors, providing end-to-end manufacturing from vector design to aseptic drug product filling.
  3. Technology Platform Licensing: DiNAQOR licenses its LRP delivery platform technology to pharmaceutical and biotechnology partners for use with their therapeutic assets, offering differentiated delivery solutions that enhance therapeutic index.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

DiNAQOR product offering

Product offering

Core offering

DiNAQOR is a Swiss-headquartered life science company builder that creates and scales focused biotechnology companies around differentiated gene therapy technology platforms. It combines proprietary Engineered Heart Tissue (EHT) technology, a closed-loop Loco-Regional Perfusion (LRP) delivery system, and AAV vector engineering to advance monogenic cardiomyopathy and renal disease programs. Revenue is generated through licensing deals, milestone payments, royalties, and CDMO services delivered via its portfolio subsidiaries (DiNAMIQS, DiNABIOS, DiNATEQ AG, DAiNA).

Product overview

DiNAQOR is a Swiss-headquartered life science company builder operating a multi-platform portfolio of distinct subsidiaries and technology offerings. The core comprises DiNATEQ AG (precision drug delivery MedTech advancing the closed-loop Loco-Regional Perfusion platform), DiNAMIQS (AAV viral vector CDMO spun out and now majority-owned by Siegfried), DiNABIOS (AI-driven human cell and tissue CDMO), and DAiNA (N=1 precision oncology). Underpinning the portfolio are two proprietary technology platforms: Engineered Heart Tissue (EHT) based on hiPSC cardiomyocytes, and the Loco-Regional Perfusion (LRP) system for organ-isolated delivery. The therapeutic pipeline includes multiple gene therapy programs spanning monogenic cardiomyopathies (DINA-001 through DINA-006 covering HCM, ARVC, DCM) and monogenic renal diseases (DINAK-001 through DINAK-004 for ADPKD and Glomerular Diseases), with programs partnered with BioMarin, Lonza, and UCL.

Differentiator

Problem solved

Functional benefit

Brands

  • DiNAMIQS: CDMO for advanced medicine providing GMP-compatible capabilities and scalable viral vector manufacturing services.
  • DiNABIOS
  • DiNATEQ AG
  • DAiNA

Products and services

  • DiNAMIQS (AAV Viral Vector CDMO)
  • DiNABIOS (Human Tissue & Stem Cell CDMO)
  • DiNATEQ AG (Loco-Regional Perfusion Delivery Platform)
  • DAiNA (N=1 Precision Oncology Platform)
  • Engineered Heart Tissue (EHT) Technology Platform
  • LRP Delivery Platform Licensing

Quantifiable outcome

  • Up to 69,000-fold higher local payload concentration compared to conventional intravenous administration
  • +3 more outcomes

Companies that use DiNAQOR

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

DiNAQOR technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

DiNAQOR partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Charité – Universitätsmedizin BerlincoreStrategic or Co-development Partner · 23 December 2025Academic partnership for development of closed-loop loco-regional perfusion (LRP) platform. Professor Maximilian Y. Emmert led the landmark study published in JACC: Basic to Translational Science demonstrating the LRP technology.
  • ETH ZurichcoreStrategic or Co-development Partner · 23 December 2025Academic partner in landmark LRP delivery platform research published in JACC: Basic to Translational Science.
  • Siegfried AG (DiNAMIQS)coreStrategic or Co-development Partner · 29 September 2025DiNAMIQS, established in 2022 and spun out from DiNAQOR as independent entity in 2023, has been acquired with 95% equity by Siegfried. New cGMP viral vector manufacturing facility inaugurated, enabling end-to-end manufacturing from vector design to drug product filling.
  • Siegfried Holding AGcoreStrategic or Co-development Partner · 4 May 2023DiNAQOR sold 95% stake in DiNAMIQS to Siegfried, who is building a high-end GMP compliant facility for viral vector manufacturing at 500L scale. DiNAQOR remains a minority equity holder and close partner. Investment was mid double-digit millions Swiss Francs.
  • Children's Medical Research Institute (CMRI)minorStrategic or Co-development Partner · 10 January 2022Research collaboration to develop novel bioengineered AAV capsids for cardiac-specific gene therapy delivery. CMRI provides AAV capsid library; DiNAQOR provides EHT technology for screening. DiNAQOR has option to exclusive license co-developed capsids for cardiovascular and kidney diseases.
  • EHT Technologies GmbHcoreTechnology or Integration · 19 January 2021DiNAQOR acquired EHT Technologies GmbH, a Germany-based engineered heart tissue (EHT) technology platform company founded in 2015 based on research at University Medical Center Hamburg-Eppendorf.
  • BioMarin PharmaceuticalcoreStrategic or Co-development Partner · 3 May 2020Preclinical collaboration and license agreement to develop gene therapies for rare genetic cardiomyopathies. DiNAQOR received undisclosed upfront payment and is eligible for development, regulatory, and commercial milestones plus tiered royalties. Covers DiNA-001 for MYBPC3 HCM with option to extend to other programs.
  • UCL (University College London)coreStrategic or Co-development Partner · 13 January 2020Research collaboration and exclusive license agreement with UCL Business Ltd to develop gene therapies for monogenic cardiomyopathies. DiNAQOR obtains worldwide rights to therapies developed. Royalties to UCL upon commercialization. Based on research of Professor Thomas Voit at UCL GOSH Institute of Child Health.
  • LonzacoreStrategic or Co-development Partner · 26 November 2019Strategic collaboration for DiNAQOR's AAV gene therapy production system. Lonza provides preclinical, clinical and commercial production support for DiNA-001 at Houston, TX facility. Focus on MYBPC3 cardiomyopathies.

Scale indicators6 records

Recent moves11 records

Expansion highlights6 records

DiNAQOR competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

DiNAQOR social profiles

Digital presence

DiNAQOR financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DiNAQOR leadership team

Management profile

Number of profiles

Profiles8 records

DiNAQOR subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

DiNAQOR funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DiNAQOR M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DiNAQOR

What does DiNAQOR do?

DiNAQOR is a Swiss-headquartered life science company builder that creates and scales focused biotechnology companies around differentiated gene therapy technology platforms. It combines proprietary Engineered Heart Tissue (EHT) technology, a closed-loop Loco-Regional Perfusion (LRP) delivery system, and AAV vector engineering to advance monogenic cardiomyopathy and renal disease programs. Revenue is generated through licensing deals, milestone payments, royalties, and CDMO services delivered via its portfolio subsidiaries (DiNAMIQS, DiNABIOS, DiNATEQ AG, DAiNA).

Is DiNAQOR a public or private company?

DiNAQOR is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DiNAQOR founded?

DiNAQOR was founded in 2019. It employs 1 to 10 people.

Where is DiNAQOR based?

DiNAQOR is headquartered in Pfäffikon, Switzerland, in the Europe region.

How does DiNAQOR make money?

Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are manufacturing Services and technology Platform Licensing.

Does DiNAQOR have an API?

No public API is recorded for DiNAQOR.

What industry is DiNAQOR in?

DiNAQOR's product category is Gene Therapy & Biotechnology Platforms. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NatureThe DiNAQOR group: a disruptive holistic approach to genetic therapiesDiNAQOR AG, a Swiss genetic-medicine company, is developing organ-specific gene therapies using a modular platform with adeno-associated vectors and loco-regional perfusion delivery. Its lead candidate BMN-293 is in IND-enabling studies for hypertrophic cardiomyopathy, with a kidney pipeline and plans to expand to other organs.startupticker.chSeasoned executives to drive startups in the next phaseFive life sciences and biotech startups—4D Lifetec, Zippsafe, Distalmotion, Anjarium, and DiNaQor—have appointed new senior executives to drive their next growth phase, drawing on experience from major pharmaceutical and medical device companies. Distalmotion notably closed a USD 90 million Series E financing round and is preparing for FDA certification, having established its Dexter surgical robot in routine clinical use across select European markets. The appointments underscore a broader trend of Swiss and European biotech startups strengthening leadership with experienced executives to scale operations and expand into new markets including the United States.PR NewswireDiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to PatientsDiNAQOR launched DiNAQOR DiNAMIQS, a biomanufacturing subsidiary, to support gene therapy companies. The subsidiary offers GMP-compatible viral vector manufacturing up to 50L scale and is building a 2,400-square-meter facility for 500L scale production.PR NewswireDiNAQOR Announces Research Collaboration with Children's Medical Research Institute to Develop Novel, Cardiac Specific CapsidsDiNAQOR, a genetic medicine platform company focused on severe inherited cardiac diseases, has entered into a research collaboration with Children's Medical Research Institute (CMRI) in Australia to develop novel bioengineered adeno-associated virus (AAV) capsids for cardiac-specific gene therapy delivery. Under the agreement, DiNAQOR has the option to obtain an exclusive license for capsids co-developed with CMRI for cardiovascular and kidney diseases, and will provide its proprietary engineered heart tissue technology to screen CMRI's capsid library for cardiac-specific variants. The collaboration aims to improve targeting efficiency at lower doses through DiNAQOR's loco-regional perfusion system, potentially minimizing adverse effects and reducing gene therapy costs.PR NewswireDiNAQOR Appoints Medical Device Leader Mark Dehdashtian to Oversee New U.S.-Based Division, Device Development and ProductionDiNAQOR, a Swiss genetic medicine platform company focused on severe inherited cardiac diseases, has appointed veteran medical device leader Mark Dehdashtian as Executive Vice President of Medical Devices to oversee its newly formed U.S. division and manufacturing facility in Laguna Hills, California. Dehdashtian brings 30 years of experience including 25 years at Edwards Lifesciences where he designed delivery systems for transcatheter heart valves. The new division will develop DiNAQOR's catheter-based multi-organ access platform designed to deliver gene therapies directly to cardiac muscle, potentially improving safety and efficacy while reducing costs compared to systemic delivery methods.startupticker.chStartups welcome legendary board members aboardSwiss startups DiNAQor, Memo Therapeutics, Urban Connect, Inyova, and Asceneuron appointed new board members with industry experience. The appointments aim to support growth and development, with experts from cardiovascular, pharmaceutical, and sustainability sectors joining.PR NewswireDiNAQOR Expands Board of Directors with Three Renowned Cardiovascular Industry and Academic ExpertsDiNAQOR, a genetic medicine platform company headquartered in Pfäffikon, Switzerland, announced the expansion of its board of directors with three new cardiovascular industry and academic experts: Louis G. Lange, Steven Zelenkofske, and Silke Rickert-Sperling. The new board members bring collectively over five decades of experience spanning biotech entrepreneurship, clinical development and regulatory approvals, and cardiovascular genetics research. The company stated this expansion supports its phase of rapid growth to develop novel genetic treatments for severe inherited cardiac diseases.startupticker.chDiNAQOR acquires Germany-based companyDiNAQOR, a gene therapy platform, acquired Germany-based EHT Technologies GmbH, an engineered heart tissue platform. The acquisition aims to strengthen R&D for heart diseases, with EHT's hiPSC platform validated for gene therapy. Financial terms were not disclosed.PR NewswireDiNAQOR Acquires EHT Technologies GmbH to Advance Engineered Heart Tissue R&D CapabilitiesDiNAQOR, a Swiss-based gene therapy platform company, has acquired Germany-based EHT Technologies GmbH, a company specializing in engineered heart tissue technology using human induced pluripotent stem cells for cardiac drug development. EHT Technologies, founded in 2015 based on research from University Medical Center Hamburg-Eppendorf, provides a proprietary hiPSC platform for creating 3D hydrogel-based muscle constructs that can be transduced with AAV vectors for gene therapy applications. The acquisition aims to bridge the translational gap between animal models and human disease by enabling DiNAQOR to develop innovative cardiovascular therapeutics while reducing reliance on animal studies.